Moleculin Biotech, Inc. (LON:0K2H)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.76M -88.4% |
| Revenue (ttm) | n/a |
| Net Income | -32.09M |
| EPS | -15.12 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,091 |
| Open | 0.4307 |
| Previous Close | 0.4503 |
| Day's Range | 0.4161 - 0.4551 |
| 52-Week Range | 0.2405 - 18.4950 |
| Beta | 1.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About Moleculin Biotech
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activ... [Read more]
News
Moleculin Announces Pricing of $9.3 Million Public Offering
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,3...
Moleculin Biotech updates preliminary blinded results from MIRACLE trial Part A
Moleculin Biotech (MBRX) announced updated preliminary blinded results from Part A of its pivotal Phase 2/3 MIRACLE trial of Annamycin in combination with cytarabine for the treatment of relapsed or…
Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remiss...
Moleculin Biotech Registration statement: Registration filing
Moleculin Biotech filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
Moleculin Biotech Registration statement: Registration filing
Moleculin Biotech filed a registration statement on July 30, 2026, providing details about a securities offering with the SEC.
Moleculin Biotech files to sell 4.57M shares of common stock, warrants
Roth Capital Partners is exclusive placement agent in connection with this offering.
Moleculin Biotech Registration statement: Registration filing
Moleculin Biotech filed a registration statement on July 29, 2026, providing details about a securities offering with the SEC.
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin,...
Moleculin Biotech announces unblinded efficacy results from MIRACLE trial Part A
Moleculin Biotech (MBRX) announced preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the company’s pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-t...
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full intent-to-treat (ITT) basis with no patient exclusions Com...
Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity as key drivers
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
- Access the segment here
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead dru...
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Early blinded results show 40% composite complete remission rate across difficult-to-treat AML patient population in MIRACLE Trial
Moleculin Biotech Quarterly report: Q1 2026
Moleculin Biotech has published its Q1 2026 quarterly earnings report on May 14, 2026.
Moleculin Biotech Earnings release: Q1 2026
Moleculin Biotech released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30
Moleculin Biotech (MBRX) announced it is approaching the first unblinding of data from its pivotal Phase 2B/3 “MIRACLE” trial evaluating Annamycin in combination with cytarabine for the treatment of s...
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care First 45-subject data unblinding expected before June 30, 2026 ...
Moleculin announces publication on cardiac safety profiloe of annamycin
Moleculin Biotech (MBRX) announced the publication of an abstract at the European Hematology Association 2026 Congress highlighting the cardiac safety profile of Annamycin, the Company’s next-generati...
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction
Moleculin Biotech issued liposomal Annamycin patent in Hong Kong
Moleculin Biotech (MBRX) announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal ...
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or th...
Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annam...